Nordklint, Azra Karahasanovic http://orcid.org/0000-0003-1448-618X
Almdal, Thomas Peter
Vestergaard, Peter
Lundby-Christensen, Louise
Jørgensen, Niklas Rye
Boesgaard, Trine W.
Breum, Leif
Gade-Rasmussen, Birthe
Sneppen, Simone B.
Gluud, Christian
Hemmingsen, Bianca
Krarup, Thure
Madsbad, Sten
Mathiesen, Elisabeth R.
Perrild, Hans
Tarnow, Lise
Thorsteinsson, Birger
Vestergaard, Henrik
Lund, Søren S.
Eiken, Pia
Funding for this research was provided by:
Jascha Fonden
Osteoporosis Association for patients
the foundation of A & J C Tvergaard
Kaptajnløjtnant Harald Jensens og Hustrus Fond
Nordsjællands Hospital
Inge and Per Refshalls research grant
Danish Bone Society travel grant
Article History
Received: 2 April 2020
Accepted: 21 May 2020
First Online: 28 May 2020
Conflict of interest
: Azra Nordklint reports grants from the Jascha foundation, grants from the Osteoporosis Association for patients, grants from the foundation of A & J C Tvergaard, grants from the foundation of Captain Lieutenant Harald Jensen and Wife, grants from Inge and Per Refshalls research grant, grants from Danish Bone Society travel grant, grants from Nordsjællands Hospital, during the conduct of the study, and otherwise has no conflicts of interest to declare. Pia Eiken is an advisory board member for Amgen and Eli Lilly, and on the speakers’ bureau for Amgen and Eli Lilly, and own shares in Novo Nordisk A/S. Louise Lundby Christensen owns shares in Novo Nordisk A/S. Thomas Almdal owns shares in Novo Nordisk A/S. Søren S. Lund has previously published his opinion about the clinical effects of metformin treatment. Søren S. Lund owns shares in Novo Nordisk A/S and shares in dynamically traded investment funds, which may own stocks from pharmaceutical companies. Søren S. Lund has reported former employment at Steno Diabetes Center, which is a diabetes hospital and academic institution previously owned by Novo Nordisk. Søren S. Lund is now employed at Boehringer Ingelheim International GmbH, Ingelheim, Germany. Søren S. Lund’s contribution was his alone and does not necessarily reflect the official position of Boehringer Ingelheim. Trine W. Boesgaard owns shares in Novo Nordisk A/S. Trine W. Boesgaard has reported former employment at Steno Diabetes Center, which is a diabetes hospital and academic institution previously owned by Novo Nordisk. Trine W. Boesgaard is now employed at Novo Nordisk. Trine W Boesgaard’s contribution was hers alone and does not necessarily reflect the official position of Novo Nordisk. Peter Vestergaard, Leif Breum, Birthe Gade-Rasmussen, Simone B Sneppen, Christian Gluud, Bianca Hemmingsen, Thure Krarup, Sten Madsbad, Elisabeth R Mathiesen, Hans Perrild, Lise Tarnow, Birger Thorsteinsson, Niklas Rye Jørgensen and Henrik Vestergaard have no known conflicts of interest to declare.